Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Schönebeck – page 18

297 clinical trials in Schönebeck, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Schönebeck at a glance
297
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

297 trials in Schönebeck

Open in trial search

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Colitis ulcerative

Not recruiting

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Metronidazole
  • Sponsor:Friedrich-Schiller-Universitaet Jena

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.